Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Response to Comment on "High Systemic Immune-inflammation Index Is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma".

Schoppmann SF, Jomrich G.

Ann Surg. 2019 Oct 31. doi: 10.1097/SLA.0000000000003681. [Epub ahead of print] No abstract available.

PMID:
31688274
2.

The Oncogene AF1Q is Associated with WNT and STAT Signaling and Offers a Novel Independent Prognostic Marker in Patients with Resectable Esophageal Cancer.

Gruber ES, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, Jomrich G, Schoppmann SF, Gnant M, Tse W, Kenner L.

Cells. 2019 Oct 30;8(11). pii: E1357. doi: 10.3390/cells8111357.

3.

Ineffective Esophageal Motility in Patients with GERD is no Contraindication for Nissen Fundoplication.

Nikolic M, Schwameis K, Kristo I, Paireder M, Matic A, Semmler G, Semmler L, Schoppmann SF.

World J Surg. 2019 Oct 11. doi: 10.1007/s00268-019-05229-y. [Epub ahead of print]

PMID:
31605176
4.

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas.

Jomrich G, Hudec X, Harpain F, Winkler D, Timelthaler G, Mohr T, Marian B, Schoppmann SF.

Cells. 2019 Sep 16;8(9). pii: E1092. doi: 10.3390/cells8091092.

5.

High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma.

Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, Asari R, Schoppmann SF.

Ann Surg. 2019 Aug 16. doi: 10.1097/SLA.0000000000003370. [Epub ahead of print]

PMID:
31425286
6.

Modern Esophageal Function Testing and Gastroesophageal Reflux Disease in Morbidly Obese Patients.

Kristo I, Paireder M, Jomrich G, Felsenreich DM, Nikolic M, Langer FB, Prager G, Schoppmann SF.

Obes Surg. 2019 Nov;29(11):3536-3541. doi: 10.1007/s11695-019-04020-1.

PMID:
31201693
7.

High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma.

Jomrich G, Hollenstein M, John M, Ristl R, Paireder M, Kristo I, Asari R, Schoppmann SF.

Ann Surg Oncol. 2019 Apr;26(4):976-985. doi: 10.1245/s10434-019-07186-1. Epub 2019 Jan 31.

8.

Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?

Schoppmann SF, Kristo I, Riegler M.

Transl Gastroenterol Hepatol. 2018 Dec 5;3:101. doi: 10.21037/tgh.2018.11.07. eCollection 2018. Review.

9.

Electrical lower esophageal sphincter augmentation in patients with GERD and severe ineffective esophageal motility-a safety and efficacy study.

Paireder M, Kristo I, Asari R, Jomrich G, Steindl J, Rieder E, Schoppmann SF.

Surg Endosc. 2019 Nov;33(11):3623-3628. doi: 10.1007/s00464-018-06649-y. Epub 2019 Jan 22.

10.

• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.

Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group.

Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11.

11.

Morbidity in open versus minimally invasive hybrid esophagectomy (MIOMIE): Long-term results of a randomized controlled clinical study.

Paireder M, Asari R, Kristo I, Rieder E, Zacherl J, Kabon B, Fleischmann E, Schoppmann SF.

Eur Surg. 2018;50(6):249-255. doi: 10.1007/s10353-018-0552-y. Epub 2018 Aug 7.

12.

Swallowing MRI-a reliable method for the evaluation of the postoperative gastroesophageal situs after Nissen fundoplication.

Arnoldner MA, Kristo I, Paireder M, Cosentini EP, Schima W, Weber M, Schoppmann SF, Kulinna-Cosentini C.

Eur Radiol. 2019 Aug;29(8):4400-4407. doi: 10.1007/s00330-018-5779-2. Epub 2018 Nov 12.

13.

A Diagnostic Algorithm That Combines Quantitative 18F-FDG PET Parameters and Contrast-Enhanced CT Improves Posttherapeutic Locoregional Restaging and Prognostication of Survival in Patients With Esophageal Cancer.

Tamandl D, Fueger B, Haug A, Schmid R, Stift J, Schoppmann SF, Ilhan-Mutlu A, Ba-Ssalamah A.

Clin Nucl Med. 2019 Jan;44(1):e13-e21. doi: 10.1097/RLU.0000000000002366.

PMID:
30418211
14.

Persistent dysphagia is a rare problem after laparoscopic Nissen fundoplication.

Nikolic M, Schwameis K, Semmler G, Asari R, Semmler L, Steindl A, Mosleh BO, Schoppmann SF.

Surg Endosc. 2019 Apr;33(4):1196-1205. doi: 10.1007/s00464-018-6396-5. Epub 2018 Aug 31.

15.

Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors.

Kristo I, Schwameis K, Maschke S, Kainz A, Rieder E, Paireder M, Jomrich G, Schoppmann SF.

Sci Rep. 2018 Jul 2;8(1):9949. doi: 10.1038/s41598-018-27756-9.

16.

PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.

Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, Schoppmann SF.

Oncoimmunology. 2018 Mar 13;7(6):e1435226. doi: 10.1080/2162402X.2018.1435226. eCollection 2018.

17.

Alternative therapies for GERD: a way to personalized antireflux surgery.

Rieder E, Riegler M, Simić AP, Skrobić OM, Bonavina L, Gurski R, Paireder M, Castell DO, Schoppmann SF.

Ann N Y Acad Sci. 2018 Dec;1434(1):360-369. doi: 10.1111/nyas.13851. Epub 2018 May 17.

PMID:
29774563
18.

Crural Closure improves Outcomes of Magnetic Sphincter Augmentation in GERD patients with Hiatal Hernia.

Schwameis K, Nikolic M, Castellano DGM, Steindl A, Macheck S, Riegler M, Kristo I, Zörner B, Schoppmann SF.

Sci Rep. 2018 May 9;8(1):7319. doi: 10.1038/s41598-018-24322-1.

19.

Electrical Stimulation of the Lower Esophageal Sphincter to Treat Gastroesophageal Reflux After POEM.

Rieder E, Paireder M, Kristo I, Schwameis K, Schoppmann SF.

Surg Innov. 2018 Aug;25(4):346-349. doi: 10.1177/1553350618768129. Epub 2018 May 10.

PMID:
29742979
20.

Results of Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease.

Schwameis K, Nikolic M, Morales Castellano DG, Steindl A, Macheck S, Kristo I, Zörner B, Schoppmann SF.

World J Surg. 2018 Oct;42(10):3263-3269. doi: 10.1007/s00268-018-4608-8.

21.

MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas.

Jomrich G, Maroske F, Stieger J, Preusser M, Ilhan-Mutlu A, Winkler D, Kristo I, Paireder M, Schoppmann SF.

J Cancer. 2018 Jan 1;9(3):460-468. doi: 10.7150/jca.22310. eCollection 2018.

22.

The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction.

Jomrich G, Hollenstein M, John M, Baierl A, Paireder M, Kristo I, Ilhan-Mutlu A, Asari R, Preusser M, Schoppmann SF.

Oncotarget. 2018 Jan 8;9(6):6968-6976. doi: 10.18632/oncotarget.24087. eCollection 2018 Jan 23.

23.

Dysphagia severity is related to the amplitude of distal contractile integral in patients with Jackhammer esophagus.

Kristo I, Schwameis K, Paireder M, Jomrich G, Kainz A, Schoppmann SF.

Neurogastroenterol Motil. 2018 May;30(5):e13276. doi: 10.1111/nmo.13276. Epub 2017 Dec 21.

PMID:
29266608
24.

Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.

Ilhan-Mutlu A, Taghizadeh H, Beer A, Dolak W, Ba-Ssalamah A, Schoppmann SF, Hejna M, Birner P, Preusser M.

Cancer Biol Ther. 2018 Mar 4;19(3):169-174. doi: 10.1080/15384047.2017.1414759. Epub 2018 Jan 17.

25.

Update on the management of Barrett's esophagus in Austria.

Riegler M, Kristo I, Nikolic M, Rieder E, Schoppmann SF.

Eur Surg. 2017;49(6):282-287. doi: 10.1007/s10353-017-0504-y. Epub 2017 Dec 4.

26.

Dietary sugar and Barrett's esophagus.

Riegler M, Kristo I, Asari R, Rieder E, Schoppmann SF.

Eur Surg. 2017;49(6):279-281. doi: 10.1007/s10353-017-0494-9. Epub 2017 Oct 24.

27.

PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer.

Kollmann D, Schweiger T, Schwarz S, Ignatova D, Chang YT, Lewik G, Schoppmann SF, Hoetzenecker W, Klepetko W, Guenova E, Hoetzenecker K.

Oncoimmunology. 2017 Aug 18;6(9):e1331194. doi: 10.1080/2162402X.2017.1331194. eCollection 2017.

28.

Radiofrequency ablation in patients with large cervical heterotopic gastric mucosa and globus sensation: Closing the treatment gap.

Kristo I, Rieder E, Paireder M, Schwameis K, Jomrich G, Dolak W, Parzefall T, Riegler M, Asari R, Schoppmann SF.

Dig Endosc. 2018 Mar;30(2):212-218. doi: 10.1111/den.12959. Epub 2017 Oct 3.

PMID:
28884487
29.

External validation of the NUn score for predicting anastomotic leakage after oesophageal resection.

Paireder M, Jomrich G, Asari R, Kristo I, Gleiss A, Preusser M, Schoppmann SF.

Sci Rep. 2017 Aug 29;7(1):9725. doi: 10.1038/s41598-017-10084-9.

30.

Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer.

Jomrich G, Paireder M, Gleiss A, Kristo I, Harpain L, Schoppmann SF.

Gastroenterol Res Pract. 2017;2017:1678584. doi: 10.1155/2017/1678584. Epub 2017 Jun 27.

31.

Tension-Free Inlay Repair of Large Hiatal Hernias Using Dual-Sided Composite PTFE/ePTFE Meshes in Laparoscopic Surgery for Gastroesophageal Reflux Disease.

Prusa AM, Kristo I, Rieder E, Ringhofer C, Asari R, Miholic J, Schoppmann SF.

J Laparoendosc Adv Surg Tech A. 2017 Jul;27(7):710-714. doi: 10.1089/lap.2016.0371. Epub 2017 Apr 26.

PMID:
28445106
32.

Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma.

Kollmann D, Ignatova D, Jedamzik J, Chang YT, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, Hoetzenecker W, Schatton T, Asari R, Preusser M, Guenova E, Schoppmann SF.

Ann Surg Oncol. 2017 Sep;24(9):2698-2706. doi: 10.1245/s10434-017-5858-7. Epub 2017 Apr 20.

33.

Endoscopic stent suture fixation for prevention of esophageal stent migration during prolonged dilatation for achalasia treatment.

Rieder E, Asari R, Paireder M, Lenglinger J, Schoppmann SF.

Dis Esophagus. 2017 Apr 1;30(4):1-6. doi: 10.1093/dote/dow002.

PMID:
28375470
34.

Waist to hip ratio is a better predictor of esophageal acid exposure than body mass index.

Ringhofer C, Lenglinger J, Riegler M, Kristo I, Kainz A, Schoppmann SF.

Neurogastroenterol Motil. 2017 Jul;29(7). doi: 10.1111/nmo.13033. Epub 2017 Jan 29.

PMID:
28133854
35.

Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.

Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A, Schoppmann SF.

Eur J Surg Oncol. 2017 Feb;43(2):478-484. doi: 10.1016/j.ejso.2016.11.015. Epub 2016 Dec 14.

PMID:
28024944
36.

Targeted therapy in gastric cancer.

Jomrich G, Schoppmann SF.

Eur Surg. 2016;48(5):278-284. Epub 2016 Mar 7.

37.

A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors.

Dolak W, Beer A, Kristo I, Tribl B, Asari R, Schöniger-Hekele M, Wrba F, Schoppmann SF, Trauner M, Püspök A.

Gastrointest Endosc. 2016 Dec;84(6):924-929. doi: 10.1016/j.gie.2016.04.019. Epub 2016 Apr 22.

PMID:
27109457
38.

Lymphovascular invasion of tumor cells in lymph node metastases has a negative impact on survival in esophageal cancer.

Schiefer AI, Schoppmann SF, Birner P.

Surgery. 2016 Aug;160(2):331-40. doi: 10.1016/j.surg.2016.02.034. Epub 2016 Apr 14.

PMID:
27085684
39.

Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer.

Tamandl D, Ta J, Schmid R, Preusser M, Paireder M, Schoppmann SF, Haug A, Ba-Ssalamah A.

Eur J Radiol. 2016 Mar;85(3):540-5. doi: 10.1016/j.ejrad.2016.01.002. Epub 2016 Jan 12.

PMID:
26860665
40.

Should antireflux surgery be considered after successful endoscopic treatment of Barrett's esophagus with dysplasia and early cancer?

Kristo I, Riegler M, Schoppmann SF.

Endoscopy. 2016 Jan;48(1):92. doi: 10.1055/s-0034-1393166. Epub 2015 Dec 28. No abstract available.

PMID:
26710282
41.

MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium.

Drahos J, Schwameis K, Orzolek LD, Hao H, Birner P, Taylor PR, Pfeiffer RM, Schoppmann SF, Cook MB.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):429-37. doi: 10.1158/1055-9965.EPI-15-0161. Epub 2015 Nov 24.

42.

Targeting HER 2 and angiogenesis in gastric cancer.

Jomrich G, Schoppmann SF.

Expert Rev Anticancer Ther. 2016;16(1):111-22. doi: 10.1586/14737140.2016.1121110. Epub 2015 Dec 5. Review.

PMID:
26567753
43.

Laryngopharyngeal reflux COPD to uncover reflux and columnar lined esophagus.

Kristo I, Riegler M, Schoppmann SF.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 30;10:2095-6. doi: 10.2147/COPD.S93711. eCollection 2015. No abstract available.

44.

Abdominal drainage after liver transplantation from deceased donors.

Schwarz C, Soliman T, Györi G, Silberhumer G, Schoppmann SF, Mühlbacher F, Berlakovich GA.

Langenbecks Arch Surg. 2015 Oct;400(7):813-9. doi: 10.1007/s00423-015-1338-3. Epub 2015 Sep 4.

PMID:
26341224
45.

Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer.

Tamandl D, Paireder M, Asari R, Baltzer PA, Schoppmann SF, Ba-Ssalamah A.

Eur Radiol. 2016 May;26(5):1359-67. doi: 10.1007/s00330-015-3963-1. Epub 2015 Sep 3.

PMID:
26334504
46.

A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection.

Dolak W, Mesteri I, Asari R, Preusser M, Tribl B, Wrba F, Schoppmann SF, Hejna M, Trauner M, Häfner M, Püspök A.

Endosc Int Open. 2015 Feb;3(1):E19-28. doi: 10.1055/s-0034-1377935. Epub 2014 Oct 24.

47.

Erratum. Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer.

Ilhan-Mutlu A, Starlinger P, Perkmann T, Schoppmann SF, Preusser M, Birner P.

Biomark Med. 2015;9(6):617. doi: 10.2217/bmm.15.24. No abstract available.

48.

Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.

Tamandl D, Gore RM, Fueger B, Kinsperger P, Hejna M, Paireder M, Haug A, Schoppmann SF, Ba-Ssalamah A.

Eur Radiol. 2016 Feb;26(2):311-21. doi: 10.1007/s00330-015-3860-7. Epub 2015 Jun 5.

PMID:
26040648
49.

microRNA-21 expression is elevated in esophageal adenocarcinoma after neoadjuvant chemotherapy.

Ilhan-Mutlu A, Tezcan G, Schoppmann SF, Preusser M, Spyridoula K, Karanikas G, Birner P.

Cancer Invest. 2015 Jul;33(6):246-50. doi: 10.3109/07357907.2015.1024319. Epub 2015 May 7.

PMID:
25950983
50.

Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer.

Ilhan-Mutlu A, Starlinger P, Perkmann T, Schoppmann SF, Preusser M, Birner P.

Biomark Med. 2015;9(4):327-35. doi: 10.2217/bmm.14.111. Erratum in: Biomark Med. 2015;9(6):617.

PMID:
25808437

Supplemental Content

Loading ...
Support Center